Shares of Alphatec Holdings (NASDAQ: ATEC), a leading medical technology company focused on spinal disorder treatments, surged by 30.43% in trading on October 31, 2024, following the company's impressive third-quarter 2024 financial results and raised full-year guidance.
For the quarter ended September 30, 2024, Alphatec reported record revenue of $151 million, a 27% increase compared to the same period last year. This strong performance was driven by a remarkable 30% year-over-year growth in surgical revenue, surpassing analyst expectations of $147.2 million. Additionally, the company achieved a 19% growth in new surgeon adoption, a key leading indicator of future growth potential.
Building on this momentum, Alphatec raised its full-year 2024 revenue guidance to $605 million, representing a 25% increase compared to the previous year. The company also increased its full-year adjusted EBITDA guidance to $27 million, up from the previous expectation of $25.5 million, reflecting its commitment to expanding profitability and improving cash flow.
While Alphatec reported a net loss of $39.6 million for the quarter, its adjusted EBITDA margin improved significantly to 4.9%, up from -0.4% in the same quarter last year, indicating progress towards profitability. The company also announced an expansion of its existing term loan facility by $50 million, increasing its total capacity to $200 million and providing additional financial flexibility.
Analysts generally maintained positive ratings and price targets on Alphatec, citing its strong growth prospects and strategic initiatives, such as driving adoption through surgeon training and its ecosystem of tools and technologies aimed at improving surgical outcomes. However, some analysts cautioned about ongoing risks and financial constraints, including managing spending and resources effectively, converting trained surgeons into active users, and addressing upcoming debt maturities.
Comments